Compare Cassava Sciences Inc (FLNA) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs JPMorgan Chase & Co — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while JPMorgan Chase & Co trades at $362.08 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 20154.3× Cassava Sciences Inc's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | JPM | |
|---|---|---|
Market Cap | $47.75M | $962.37B |
Sector | Health | Financials |
52-Week High | $4.64 | $362.04 |
52-Week Low | $0.87 | $282.84 |
Enterprise Value | -$34.93M | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings have shown strength with beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue and net income have grown steadily, with 2025 revenue at $181.85B and net income at $57.05B, though cash flow from operations remains negative. The stock exhibits strong institutional interest and a moderate buy rating from analysts.
The outlook for JPM is positive, supported by robust profitability metrics like an 18.43% ROE and a net income margin of 33.38%. Key risks include geopolitical tensions impacting banking sectors and persistent negative operating cash flows. Upside potential exists if the company meets or exceeds future earnings expectations, with the next catalyst being Q3 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
